Danielle N Mitchell

US Patent:

20120294797, Nov 22, 2012

Filed:

May 21, 2012

Appl. No.:

13/476465

Inventors:

Brian Robert Kovacevich - Snohomish WA, US
Leon F. Garcia-Martinez - Woodinville WA, US
Katie Olson - Kenmore WA, US
Benjamin H. Dutzar - Seattle WA, US
Jens J. Billgren - Seattle WA, US
John A. Latham - Seattle WA, US
Danielle M. Mitchell - Seattle WA, US
Patricia Dianne Mcneill - Federal Way WA, US
Nicole M. Janson - Edmonds WA, US
Maria-Cristina Loomis - Bothell WA, US

International Classification:

C07K 16/18
C12N 15/63
C12N 1/19
A61K 39/395
A61K 49/00
A61K 51/00
C12Q 1/68
C12N 5/10
C12N 1/15
C12N 1/21
A61P 25/06
A61P 3/00
A61P 35/00
A61P 25/00
A61P 29/00
A61P 19/08
A61P 1/16
A61P 13/12
A61P 13/00
A61P 3/10
A61P 37/00
A61P 9/00
A61P 19/02
A61P 11/00
A61P 11/06
A61P 25/36
A61P 15/00
A61P 17/00
A61P 17/06
A61P 25/08
A61P 25/28
A61P 17/04
A61P 1/00
A61P 37/08
A61P 31/00
C12N 15/13

US Classification:

424 111, 5303891, 5303873, 5303913, 5303917, 536 2353, 4353201, 43525423, 4241721, 424 91, 424 96, 5303911, 4241331, 435 61, 435332, 43525411, 43525233, 4241581

Abstract:

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

US Patent:

20130045888, Feb 21, 2013

Filed:

Aug 20, 2012

Appl. No.:

13/589584

Inventors:

Danielle Marie Mitchell - Seattle WA, US
Leon F. Garcia-Martinez - Woodinville WA, US
Patricia Dianne McNeill - Federal Way WA, US
Ethan Wayne Ojala - Snohomish WA, US
Mehmet Inan - Antalya, TR
John Latham - Seattle WA, US

International Classification:

C40B 30/04
C12P 21/00
C12N 1/19

US Classification:

506 9, 4352551, 4352555, 435 696

Abstract:

Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as

US Patent:

20130302399, Nov 14, 2013

Filed:

Mar 12, 2013

Appl. No.:

13/795674

Inventors:

Andrew Lawrence Feldhaus - Lynnwood WA, US
Leon F. Garcia-Martinez - Woodinville WA, US
Benjamin H. Dutzar - Seattle WA, US
Ethan Wayne Ojala - Snohomish WA, US
Brian Robert Kovacevich - Snohomish WA, US
Katie Olson - Kenmore WA, US
Pei Fan - Bothell WA, US
Jens Billgren - Seattle WA, US
Erica Ann Stewart - Shoreline WA, US
Corinne C. Akatsuka - Hilo HI, US
Patricia Dianne McNeill - Federal Way WA, US
Danielle Marie Mitchell - Seattle WA, US
Dan Scott Allison - Lake Forrest Park WA, US
John A. Latham - Seattle WA, US

International Classification:

C07K 16/40
A61K 45/06
A61K 39/395

US Classification:

424450, 5303898, 5303917, 435188, 5303872, 4241581, 536 2353, 4353201, 435338, 4352523, 43525411, 4352542, 43525423, 43525422, 43525421, 4352543, 4352547, 4352546, 4352544, 435 696, 435 74, 5303913

Abstract:

The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.

US Patent:

20130336975, Dec 19, 2013

Filed:

Mar 15, 2013

Appl. No.:

13/833338

Inventors:

Benjamin H. Dutzar - Seattle WA, US
Brian R. Kovacevich - Snohomish WA, US
Patricia Dianne McNeill - Federal Way WA, US
Danielle M. Mitchell - Seattle WA, US
Ethan W. Ojala - Snohomish WA, US
Pei Fan - Bothell WA, US
Jens Billgren - Seattle WA, US
Erica A. Stewart - Shoreline WA, US
Corinne C. Akatsuka - Hilo HI, US
Betty Yu-Ching Chang - Cupertino CA, US
John A. Latham - Seattle WA, US
Leon F. Garcia-Martinez - Woodinville WA, US

International Classification:

C07K 16/22

US Classification:

4241351, 5303892, 5303873, 5303913, 5303917, 536 2353, 4353201, 435335, 4352542, 4352523, 43525411, 435419, 4241581, 435 71, 435328

Abstract:

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

US Patent:

20120148490, Jun 14, 2012

Filed:

Dec 1, 2011

Appl. No.:

13/309295

Inventors:

Benjamin H. Dutzar - Seattle WA, US
Brian R. Kovacevich - Snohomish WA, US
Patricia Dianne NcNeill - Federal Way WA, US
Danielle M. Mitchell - Seattle WA, US
Ethan W. Ojala - Snohomish WA, US
Pei Fan - Bothell WA, US
Jens Billgren - Seattle WA, US
Erica A. Stewart - Shoreline WA, US
Corinne C. Akatsuka - Hilo HI, US
Betty Yu-Ching Chang - Cupertino CA, US
John A. Latham - Seattle WA, US
Leon F. Garcia-Martinez - Woodinville WA, US

International Classification:

A61K 39/395
C12N 15/13
A61K 49/00
A61K 51/10
A61P 29/00
A61P 25/00
A61P 19/10
A61P 35/00
A61P 1/16
A61P 25/06
A61P 31/04
A61P 21/00
C12N 15/63
C12N 5/10
C12N 1/21
C12N 1/15
C12N 1/19
C12N 9/96
C12P 21/02
A61P 37/08
C07K 16/22

US Classification:

424 149, 5303892, 5303873, 5303913, 536 2353, 4241581, 424 91, 5303917, 5303911, 4353201, 435335, 4352523, 435419, 43525411, 4352542, 43525423, 424 96, 435188, 530367, 435 696, 800 6

Abstract:

The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.

US Patent:

20220363773, Nov 17, 2022

Filed:

Dec 21, 2021

Appl. No.:

17/557440

Inventors:

- SEATTLE WA, US
Elaine T. SEWELL - Seattle WA, US
Catherine J. MCMAHAN - Seattle WA, US
David BIENVENUE - Seattle WA, US
John W. BLANKENSHIP - Seattle WA, US
Danielle MITCHELL - Seattle WA, US
Peter PAVLIK - Seattle WA, US

International Classification:

C07K 16/28
A61P 35/00
A61K 47/68
A61P 35/02
C07K 16/30
C12N 15/62

Abstract:

The present disclosure relates to protein molecules that specifically bind to CD123, which may have at least one humanized or human CD123-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD123 may have a second binding domain that binds to another target. In one embodiment, multi-specific polypeptide molecules bind both CD123-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD123-binding polypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.

US Patent:

20220242962, Aug 4, 2022

Filed:

Aug 12, 2020

Appl. No.:

17/634631

Inventors:

- Seattle WA, US
Lynda MISHER - Seattle WA, US
Danielle Marie MITCHELL - Seattle WA, US
Michelle Hase NELSON - Seattle WA, US
Peter PAVLIK - Seattle WA, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present disclosure provides antibodies that specifically bind to 4-1BB and/or OX40, including bispecific antibodies that bind to 4-1BB and OX40, and compositions comprising such antibodies. Also provided are methods for treating disorders, such as cancer, using such antibodies and compositions.

US Patent:

20210047391, Feb 18, 2021

Filed:

Jan 13, 2020

Appl. No.:

16/740699

Inventors:

- LAS VEGAS NV, US
Leon F. Garcia-Martinez - Woodinville WA, US
Katie Olson Anderson - Kirkland WA, US
Benjamin H. Dutzar - Seattle WA, US
Jens J. Billgren - Seattle WA, US
John A. Latham - Seattle WA, US
Danielle M. Mitchell - Seattle WA, US
Patricia Dianne McNeill - Federal Way WA, US
Nicole M. Janson - Seattle WA, US
Maria-Cristina Loomis - Bothell WA, US

International Classification:

C07K 16/18
A61P 25/00
C07K 16/26
A61K 31/485
A61K 39/395
A61K 49/00

Abstract:

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.